Museum-Worthy
It’s Hard to make museum-worthy art. It’s harder to make museum-worthy ads. Enter the 2024 #AICPAwards by 11:59pm PDT on Tuesday, March 12th. Winning work…
It’s Hard to make museum-worthy art. It’s harder to make museum-worthy ads. Enter the 2024 #AICPAwards by 11:59pm PDT on Tuesday, March 12th. Winning work…
Get quick stats and key facts about tobacco control.
The medical education provider had proposed a year’s worth of online content about smoking cessation backed by the tobacco giant, an internal document shows.
Nature Medicine – In a case series of six patients with multidrug-resistant rheumatoid arthritis, the CD19xCD3-targeting bispecific T cell engager blinatumomab reduced disease activity and…
PURPOSE Molecular tumor boards (MTBs) provide interventions that assist the patient’s primary oncologist’s interpretation and application of precision oncology and avoid clinical and financial toxicities…
PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with…
We’ve come together as a team with a shared mission, to raise awareness and support the Bladder Cancer Advocacy Network (BCAN), a national advocacy organization…
VivekSubbiah & colleagues delve into the @ASCO #TAPURStudy, shedding light on the importance of targeting ALL #BRAFAlterations, beyond V600E. (Re)-search continues, urging us to push…
In a phase II basket trial, the BRAF inhibitor vemurafenib showed preliminary evidence of efficacy in 13 BRAF-mutant non-melanoma tumor types, including some typically considered…
AbstractThe MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer. Although RAS mutations are the most frequent MAPK alterations, less frequent…
Abstract. The European Society for Medical Oncology defines rare cancers as 5 or fewer cases per 100,000 persons per year. For many rare cancers, no…